AdipoGen Life Sciences

UBS109

As low as CHF 40.00

In stock

Only %1 left

AG-CR1-3704-M0011 mgCHF 40.00

AG-CR1-3704-50015 x 1 mgCHF 120.00

AG-CR1-3704-M01010 mgCHF 130.00

Specifications / Handling

More Information
Product Details
Synonyms	(3E,5E)-1-Methyl-3,5-bis(2-pyridinylmethylene)-4-piperidinone; Monocarbonyl Analog of Curcumin
Product Type	Chemical
Properties
Formula	C₁₈H₁₇N₃O
MW	291.4
CAS	1258513-40-4
Purity Chemicals	≥95% (HPLC)
Appearance	Yellow solid.
Solubility	Soluble in DMSO (10mg/ml). Insoluble in water.
Identity	Determined by ¹H-NMR.
Other Product Data	Note: Always prepare and use fresh solution. We recommend to immediately use the fresh solution. In methanol and ethanol the compound decomposes rapidly.
InChi Key	VCLPNFMJSSBBKX-WFYKWJGLSA-N
Smiles	O=C(/C(CN(C)C/1)=C/C2=NC=CC=C2)C1=C\C3=CC=CC=N3
Shipping and Handling
Shipping	BLUE ICE
Short Term Storage	+4°C
Long Term Storage	-20°C
Handling Advice	Keep cool and dry. Protect from light.
Use/Stability	Stable for at least 2 years after receipt when stored at -20°C.
Documents
MSDS	Download PDF
Product Specification Sheet
Datasheet	Download PDF

Product Description

Most water soluble synthetic monocarbonyl analog of curcumin (MAC) for in vitro and in vivo application.
Potently inhibits NF-κB and its nuclear translocation by suppressing IKK-α and IKK-β, consequently leading to apoptosis.
Potent DNA hypomethylating agent. Inhibits HSP90 and NF-κB leading to downregulation of DNA methyltransferase-1 (DNMT-1) expression.
Cytotoxic against several cancers in vitro and in vivo. Shows excellent activity against xenografts of head and neck squamous cell carcinoma, pancreatic cancer, colon cancer and breast cancer.
Antiangiogenic agent. Induces the downregulation of HIF-1α, HSP90, COX-2 and VEGF in tumor samples from xenograft models compared to untreated xenografts.
Shows preventive effects on bone loss induced by breast cancer cell bone metastasis. Found to have a potential stimulating effect on osteoblastogenesis and a suppressive effect on osteoclastogenesis in vitro through Smad activation and NF-κB inhibition. May have promise in the development into an antiosteoporotic agent capable of promoting new bone formation while simultaneously reducing bone resorption.

Product-specific References

Novel curcumin analogue UBS109 potently stimulates osteoblastogenesis and suppresses osteoclastogenesis: involvement in Smad activation and NF-kB inhibition: M. Yamaguchi, et al.; Integr. Biol. 4, 905 (2012)
Novel synthetic curcumin analogues EF31 and UBS109 are potent DNA hypomethylating agents in pancreatic cancer: G. Nagaraju, et al.; Cancer Lett. 341, 195 (2013)
Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: involvement in osteoblastogenesis and osteoclastogenesis: M. Yamaguchi, et al.; Cell Tissue Res. 357, 245 (2014)
Liver S9 Fraction-Derived Metabolites of Curcumin Analogue UBS109: T.W. Moore, et al.; Med. Chem. Lett. 5, 288 (2014)
Curcumin analog UBS109 prevents bone marrow osteoblastogenesis and osteoclastogenesis disordered by coculture with breast cancer MDA-MB-231 bone metastatic cells in vitro: M. Yamaguchi, et al.; Mol. Cell Biochem. 401, 1 (2015)
Eliminating the Heart from the Curcumin Molecule: Monocarbonyl Curcumin Mimics (MACs): D. Shetty, et al.; Molecules 20, 249 (2015) (Review)
Inhibition of breast cancer metastasis to the lungs with UBS109: M. Shoji, et al.; Oncotarget 9, 36102 (2018)
Curcumin and derivatives function through protein phosphatase 2A and presenilin orthologues in Dictyostelium discoideum: M. Cocorocchio, et al.; Dis. Mod. Mechan. 11, dmm032375 (2018)

Call	+41 61 926 6040
Fax	+41 61 926 6049